Geode Capital Management
CVKD icon

Geode Capital Management’s Cadrenal Therapeutics CVKD Stock Holding History

Geode Capital Management’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.5K Sell
19,024
-2,602
-12% -$12.4K ﹤0.01% 4195
2026
Q1 		$111K Buy
21,626
+7,098
+49% +$49.8K ﹤0.01% 4108
2025
Q4 		$98.5K Buy
14,528
+1,818
+14% +$20.6K ﹤0.01% 4103
2025
Q3 		$175K Hold
12,710
– – ﹤0.01% 3967
2025
Q2 		$153K Buy
12,710
+624
+5% +$9.27K ﹤0.01% 3953
2025
Q1 		$213K Buy
12,086
+1,532
+15% +$28.2K ﹤0.01% 3828
2024
Q4 		$153K Buy
+10,554
New +$152K ﹤0.01% 3977
2024
Q3 		– Sell
-4,104
Closed -$28.9K – 4548
2024
Q2 		$28.9K Buy
4,104
+1,246
+44% +$8.62K ﹤0.01% 4394
2024
Q1 		$26.1K Buy
2,858
+275
+11% +$3.49K ﹤0.01% 4445
2023
Q4 		$27.6K Hold
2,583
– – ﹤0.01% 4461
2023
Q3 		$26.4K Buy
+2,583
New +$36.7K ﹤0.01% 4569

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
Q1WB
Quest 10 Wealth Builders Fuquay-Varina, Virginia $129M AUM 22.73% 1-Year Est. Return

Geode Capital Management's CVKD Position: Q2 2026 in Review

Geode Capital Management reduced its Cadrenal Therapeutics (CVKD) stake by 12% in Q2 2026, selling an estimated $12.4K and leaving 19,024 shares worth $63.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4195.

Geode Capital Management first reported a position in CVKD in Q3 2023 and has held it in 11 quarters since. The position peaked at $213K in Q1 2025. 19 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Geode Capital Management held 19,024 shares of Cadrenal Therapeutics worth $63.5K as of Q2 2026.
  • Geode Capital Management sold 2,602 Cadrenal Therapeutics shares in Q2 2026, an estimated $12.4K.
  • Cadrenal Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4195 holding.
  • Geode Capital Management first reported a position in Cadrenal Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Geode Capital Management's Cadrenal Therapeutics position peaked at $213K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.